Interstitial lung processes

From WikiLectures

Interstitial lung/pulmonary processes (IPP, also know as fibrotic lung processes) are immunopathological processes occurring at the level of the lung interstitium, i.e., in the interalveolar area, in the alveoli, and in the peribronchium. They prevent efficient gas exchange at the alveolar-capillary membrane and lead to respiratory insufficiency.[1]

This is a group of diseases of various etiologies, which are characterized by varying degrees of inflammatory and / or fibrotic involvement of the lung parenchyma. Lung involvement is usually manifested by exertional dyspnea, weight loss, subfebrile illness, and more frequent respiratory infections. Cor pulmonale develops with signs of right heart decompensation in later stages.[2]

Pulmonary fibrosis overview[edit | edit source]

Classification[edit | edit source]

  1. Diffuse lung processes resulting from known causes: exogenous allergic alveolitis (EAA), pneumoconiosis, post-radiation pneumonia, drug-induced lung damage (e.g., amiodarone and methotrexate);
  2. Idiopathic interstitial pneumonia: idiopathic pulmonary fibrosis (IPF); nonspecific interstitial pneumonitis; lymphocytic interstitial pneumonitis; desquamative interstitial pneumonitis; interstitial lung disease associated with respiratory bronchiolitis; cryptogenic organizing pneumonia; acute interstitial pneumonitis;
  3. Granulomatoses - sarcoidosis, pulmonary histiocytosis , granulomatosis with polyangiitis, vasculitis, etc...;
  4. Other: eosinophilic pneumonia, lymphangioleiomyomatosis, alveolar proteinosis, etc...[2][1]

Pathogenesis[edit | edit source]

Fibrin deposition along the alveolar walls plays a role in the pathogenesis → so-called hyaline membranes are formed in the alveoli. This is followed by an inflammatory phase where there is infiltration by neutrophils (later macrophages and lymphocytes), which mediate repair processes resulting in fibrosis. Another pathogenetic event is alveolar cell proliferation, organization of fibrinous exudate, collagen deposition → repair / fibrosis.[3]

Consequences of interstitial lung diseases[edit | edit source]

  • Hypoxemia (↓ p and O 2 ) especially during exertion in the initial stages with hyperventilation with a tendency towards respiratory alkalosis (↓ p and CO 2 );
  • later on, resting hypoxemia (↓ p and O 2 ) and hypoventilation manifest;
  • pulmonary hypertension → cor pulmonale.[3]

Common features[edit | edit source]

Common features include exertional and then resting shortness of breath. IPPs are often accompanied by an irritating cough. Diagnostic imaging techniques reveal reticulonodulation or honeycomb lungs. During auscultation, crepitations can be heard.[1]

Examination[edit | edit source]

In laboratory diagnostics, we choose examinations to exclude damage to other organs, basic immunological examinations, and examinations of autoantibodies. In indicated cases, exclusion of glomerular involvement, calcium metabolism, and serum angiotensin converting enzyme in patients with suspected sarcoidosis are indicated during clinical examination. It is important to examine lung function and respiratory parameters at rest, if necessary. A chest skiagram in two projections (however, a negative finding does not rule out IPP!) is necessary. Diagnostics high-resolution computed tomography (HRCT) is used to assess the type and extent of lung parenchyma involvement. In terms of invasive examinations, bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, and a lung biopsy can be used if necessary.[2]

Therapy[edit | edit source]

Pulmonary fibrosis on HRCT

We choose therapy according to etiology (if known). The first step is to stop exposure to harmful inhalants .

Pharmacotherapy[edit | edit source]

  • systemic corticotherapy at doses appropriate to the severity of the disability
    • indications: idiopathic nonspecific interstitial pneumonitis (NSIP), severe exogenous allergic alveolitis (EAA), drug-induced lung disease, eosinophilic pneumonia, cryptogenic organizing pneumonia (COP), sarcoidosis with lung function impairment;
  • systemic corticosteroid therapy in combination with other immunosuppressants (e.g., methotrexate, azathioprine, cyclophosphamide)
    • systemic connective tissue diseases, other autoimmune syndromes;
  • N-acetylcysteine ​​- idiopathic pulmonary fibrosis (IPF),
  • proton pump inhibitors - IPF,
  • inhalation bronchodilators - silicosis, coal mine pneumoconiosis,
  • inhaled corticosteroids - sarcoidosis with bronchial hyperreactivity,
  • macrolides - some forms of organizing pneumonia.[2]

Non-pharmacological treatment[edit | edit source]

  • oxygen therapy,
  • balneotherapy,
  • physiotherapy,
  • lung transplantation.[2]

Prognosis[edit | edit source]

Idiopathic pulmonary fibrosis (IPF) has the most severe prognosis - lung transplantation, treatment with pirfenidone[2] (immunosuppressant - suppresses fibroblast proliferation and production of proteins associated with fibrosis and cytokines, and also suppresses increased biosynthesis and accumulation of the extracellular matrix in response to cytokine growth factors).

Idiopathic pulmonary fibrosis (IPF)[edit | edit source]

HRCT pulmonary fibrosis

It is a diffuse, primarily fibrotic lung process.

Pathogenesis[edit | edit source]

This is probably a uniform pathological response of lung tissue to both infectious and non-infectious agents. These cause damage to the lining of the alveoli and thus result in progressive and uncontrollable scarring. The inflammatory reaction as such can occur only secondarily.

Epidemiology[edit | edit source]

  • Patients are most often between the ages of 40 and 70.
  • The incidence in women is 7.4 / 100,000 and in men 10.7 / 100,000.
  • It occurs sporadically, is equally widespread in all localities, familial cases are rare.
  • The disease is practically incurable, and even with adequate treatment, survival usually does not exceed 3-5 years.

Clinical picture[edit | edit source]

  • Onset – rolonged unproductive cough in time with worsening exertiona dyspnea, fatigue, weight loss, tachypnoe;
    • on the bases of lungs late inspiratory crepitus similar to Velcro opening[4];
    • eventually chronic hypoxia with cyanosis develops.
  • In 2/3 of the patients there are club-shaped fingers with nails in the shape of a watch glass.
  • Image of COPD without obstructive defect, in the later phase restrictive lung damage - reduction of FVC.
  • Despite the typically protracted progressively deteriorating course, acute exacerbations may occur in some patients:
    • sudden clinical deterioration;
    • decreased lung function;
    • radiological image of the so-called milk glass (indicating alveolitis).

Diagnostics[edit | edit source]

Here, HRCTs are crucial, and a typical clinical finding does not require a biopsy if systemic connective tissue diseases and an exogenous cause are excluded.

  • HRCT image of the lungs: pulmonary fibrosis with an image of the honeycomb lung in the bases of the lungs and minimal areas of active changes.
  • Histology from a lung biopsy.
  • In patients unable to undergo surgical biopsy, X-ray and bronchoscopy must be sufficient.
  • X-ray: increased lung drawing to reticulation - honeycomb lung.
  • Functional examination: restrictive ventilation disorder, pulmonary compliance disorder.

Therapy[edit | edit source]

  • Anti-inflammatory and immunosuppressive drugs are ineffective because the main pathological mechanism here is pathological fibroproduction, so they are not used in treatment today.
  • Pirfenidon – inhibits fibrosis, indicated in patients with FVC 50-80%. Dosage 3x3cps - a total of 2403 mg.
  • Nintedanib – a tyrosine kinase inhibitor on VEGFR, FGFR, and PDGFR
  • Early alveolar lesions: N-acetylcystein 3 times 600 mg (antioxidant effect).
  • Acute exacerbations: high doses of corticoids, anticoagulant therapy, and antibiotics. PPI (proton pump blockers) are given to prevent exacerbations.
  • Advanced diseases with hypoxemia: long-term home oxygen therapy and consideration of lung transplantation.
  • Corticosteroids in long-term therapy are ineffective, pbecause fibrotization is not induced by an inflammatory response. [5][6][7]

Summary video[edit | edit source]

Idiopathic pulmonary fibrosis (video in english)


Exogenous allergic alveolitis (EAA)[edit | edit source]

Exogenous allergic alveolitis (or hypersensitive pneumonitis, farmer's lung, pigeon's lung) includes a group of immunologically conditioned diseases (type III. hypersensitivity) with granulomatous inflammation in the bronchioles and alveoli. It is an interstitial pulmonary fibrosis caused by repeated contact with certain allergens. The most endangered group are workers of plant and animal production after repeated exposure to moldy hay, straw and grain. Exogenous allergic alveolitis also occurs while working with moldy malt, furs, moldy cheese, feather and bird excrement. It is rare in children and is most often caused by inhalation of organic dust from birds (pigeons, parrots, budgies).

Diagnostics[edit | edit source]

  • Patient's history, laboratory signs of inflammation, precipitating antibodies (specific IgG) in serum against including antigen
  • Chest X-ray: reticulonodular drawing with mottled volatile infiltrates
  • BAL: usually lymphocytic alveolitis, ↓ CD4/CD8
  • Chronic phase: X-ray + HRCT image of interstitial pulmonary fibrosis/honeycomb lung; restriction, lung diffusion capacity disorder, hypoxemia; lung biopsy.

Clinical picture[edit | edit source]

Acute

The acute form is reversible and develops within about 6 hours after intense antigen exposure. It expires within 48 hours. Physically, crepitus above the lung bases is demonstrable. The following characteristics are manifested:

Chronic

If antigen exposure persists, a chronic form of exogenous allergic alveolitis develops. In case of repeated exposure, lower concentrations of the respective antigen are also sufficient. Irreversible interstitial lung fibrosis (restriction disorder) occurs. The symptoms are:

Therapy[edit | edit source]

  • Elimination of antigens – necessary permanent exclusion of the workers from exposure (for occupational diseases)
  • corticoids
  • oxygen therapy.[8][9][10]


Occupational pneumoconiosis[edit | edit source]

Pneumoconiosis is a group of occupational diseases caused by long-term inhalation of air containing specific inorganic particles. The basis of lung changes is the response of immunocompetent cells to these particles, which leads to damage to the lung interstitium.

Types of diseases[edit | edit source]

Silicosis

  • Silicosis
  • asbestosis
  • pneumoconiosis
  • berylliosis
  • talcosis- occurs after exposure to talc dust (during its mining and grinding), possible clinical manifestation of the disease:
    • nodular lesions,
    • diffuse interstitial fibrosis,
    • granulomatous reactions around foreign bodies,
  • pulmonary involvement during inhalation of heavy metals - cobalt, tungsten, carbide, possible pictures of the disease:
    • chronic diffuse inflammation with pulmonary fibrosis,
    • acute and subacute interstitial disability with EAA or BOOP,
    • obstructive pulmonary disease resembling occupational asthma.

Nowadays, we encounter these diseases rather rarely (the incidence decreased due to prevention in the work environment).

Types of changes[edit | edit source]

The nature of the inflammatory changes depends on the shape and size of the inhaled particles, the length and intensity of the exposure. Inorganic particles can be divided into fibrogenic (silicosis, asbestosis) and non-fibrogenic (other) particles in terms of shape. In general, diseases caused by fibrogenic particles are worse because they do not respond to anti-inflammatory treatment and thus tend to progress permanently and their prognosis is very poor.

Manifestations of the disease[edit | edit source]

Gradual decrease in lung function, worsening cough, dyspnea, and development of respiratory insufficiency.

Diagnostics[edit | edit source]

  • History - symptoms (cough, shortness of breath), work and social history,
  • X-ray of the lungs,
  • functional lung examination (spirometry),
  • BAL - if we need to identify the inorganic particles,
  • biopsies are usually no longer performed.

Therapy[edit | edit source]

  • Disease prevention (protective equipment, work environment limits),
  • elimination of additional exposure,
  • therapy of onset infections,
  • long-term home oxygen therapy (DDOT),
  • respiratory rehabilitation,
  • lung transplantation (in indicated cases).[11]


Pulmonary manifestations in systemic connective tissue diseases[edit | edit source]

Systemic connective tissue diseases are autoimmune diseases with multiorgan impairment due to vasculitis; frequent arthritis, muscle and skin damage. The onset of fibrosing alveolitis is a response to immunocomplexes deposited in the pulmonary capillaries. The treatment is corticotherapy.[12]

Rheumatoid arthritis


Systemic lupus erythematosus
  • Pulmonary impairment in 50 to 60%: most often pleurisy, ILD, rarely acute pneumonia;
  • X-RAY: reticulonodular shadows with max. impairment of the lower lung fields;
  • therapy: corticoids + penicillamine/cyclophosphamide;
  • survival 10 to 14 years (cause of death renal failure, endarteritis or secondary pneumonia).[12]


Scleroderma (progressive systemic sclerosis)
  • ILD in up to 80% of patients [12]


Polymyositis, dermatomyositis
Sjogren's syndrome
Bechterew's disease
Crohn's disease

Postradiation lung fibrosis[edit | edit source]

Pulmonary fibrosis represents the final stage of postradiation lung changes.

Lung fibrosis on HRCT
  • After irradiation of lung tissue with ionizing radiation at doses> 8 Gy in 30 weeks.
  • Necrotic changes caused by ionizing radiation healed by a fibrotic scar.
  • Clinical manifestations: dry cough, worsening dyspnea (restriction disorder with ↓ diffusion)
  • Diff. dg: radiation pneumonitis (exudative alveolitis from pneumocyte + endothelial damage)
  • Therapy: in small infiltrates, no treatment is necessary, in symptomatic individuals corticoids
  • Risk factors: professional injury (radiologist, miner), poorly targeted radiotherapy[13]


Drug-induced pulmonary fibrosis[edit | edit source]

Drug-induced pulmonary fibrosis is a development of an intersticial pneumonia and fibrosis due to hypersensitivity or toxic effets of drugs (Template:HVLP, MTX, amiodarone, nitrofurantoin[14], inhalation of O2 in high concentrations):

  • hypersensitivity: ATB (penicilin, ampicilin, nitrofurantoin), some cytostatics (MTX),
  • direct toxicity: cytostatics (bleomycin, cyclofosfamidTemplate:HVLP) → cytostatic lungs.

It can manifest as an acute or chronic condition.[15]

Symptoms[edit | edit source]

Therapy[edit | edit source]



References[edit | edit source]

Related articles[edit | edit source]

Citations[edit | edit source]

  1. a b c HOMOLKA, Jiří, et al. Internal Medicine Volume III. first edition. Praha: nakladatelství Galen, 2001.  ISBN 80-7262-131-9 .
  2. a b c d e f ŠTERCLOVÁ, M and M VAŠÁKOVÁ. Interstitial lung processes - why is it necessary to make a correct diagnosis? Internal Med [online] . 2013, vol. 15, vol. 8-9, pp. 261-262, also available from < https://www.internimedicina.cz/pdfs/int/2013/08/06.pdf >. 
  3. a b CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007.  ISBN 978-80-7262-496-6 .
  4. KOLEKTIV, Marek. Farmakoterapie vnitřních nemocí - 4. zcela přepracované a doplněné vydání. - vydání. Grada Publishing a.s., 2010. 777 s. s. 170. ISBN 9788024726397.
  5. BENEŠ, Jiří. Studijní materiály [online]. [cit. 2010]. <http://jirben.wz.cz>.
  6. ČEŠKA, Richard, et al. Interna. 1. vydání. Praha : Triton, 2010. 855 s. ISBN 978-80-7387-423-0.
  7. VAŠÁKOVÁ, Martina. Léčba idiopatické plicní fibrózy. Remedia [online]. 2012, roč. 2012, vol. 2, s. 398-402, dostupné také z <http://www.remedia.cz/Clanky/Farmakoterapie/Lecba-idiopaticke-plicni-fibrozy/6-L-1oN.magarticle.aspx>. ISSN 0862-8947. 
  8. BENEŠ, Jiří. Study materials  [online]. [feeling. 11.3.2010]. < http://jirben.wz.cz >.
  9. CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007.  ISBN 978-80-7262-496-6 .
  10. TUČEK, Milan, Miroslav CIKRT and Daniela PELCLOVÁ. Occupational Medicine for Practice: A Guide to Recommended Standards. 1st edition. Prague: Grada Publishing, 2005. pp. 69-70. ISBN 80-247-0927-9
  11. ČEŠKA, Richard, et al. Internal. 1st edition. Prague: Triton, 2010. 855 pp. 460-465. ISBN 978-80-7387-423-0.
  12. a b c d CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007.  ISBN 978-80-7262-496-6 .
  13. CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007.  ISBN 978-80-7262-496-6 .
  14. GOEMAERE, Natascha NT, Karin GRIJM and Peter Th W VAN HAL, et al. Nitrofurantoin-induced pulmonary fibrosis: a case report. J Med Case Rep [online] . 2008, vol. 2, p. 169, also available from < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408600/?tool=pubmed >. ISSN 1752-1947. 
  15. a b CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007.  ISBN 978-80-7262-496-6 .